RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

• 2024

  Sign in to bookmark this resource.

  Sign in
• Deidre Wilkins; Ulrika Wählby-Hamrén; Yue Chang; Lindsay Clegg; Joseph Domachowske; Janet Englund
PMID: 39350745DOI: https://dx.doi.org/10.1542/peds.2024-067174

---

Access Resources

• Journal ArticleEN

About

This study compares two treatments, nirsevimab and palivizumab, for preventing RSV in infants. It describes how nirsevimab provides about 10 times more protection against RSV than palivizumab. Nirsevimab is a new medicine that lasts longer and requires only one dose to protect babies through the RSV season. The study found that babies who received nirsevimab had higher levels of protective antibodies for up to a year compared to those who got monthly doses of palivizumab. This suggests that nirsevimab could be more effective in keeping infants safe from severe RSV infections.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Heart Defects, Congenital; Infant; Lung Diseases; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Palivizumab; Antibodies, Monoclonal, Humanized; Infant, Premature

Institutions: AstraZeneca; State University of New York - Upstate Medical University; Seattle Children's Hospital; Northwestern University

---

More like this

Virtual Peer-to-Peer Learning to Enhance and Accelerate the Health System Response to COVID-19: The HHS ASPR Project ECHO COVID-19 Clinical Rounds Initiative Author links open overlay panel 2021 · U.S. Department of Health and Human Services (HHS), University of New Mexico, University of Texas at Austin, U.S. Department of Transportation Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease 2023 · State University of New York - Upstate Medical University, AstraZeneca, Dr. Georgi Stranski University Hospital, Quironsalud Madrid University Hospital, Fukuoka Children's Hospital, Hôpital Femme-Mere-Enfant The 2021 Toolkit for Emergency Preparedness and Mitigation to Combat Surge of Pediatric COVID-19 Patients in India: The World Health Organization Collaborating Center for Emergency and Trauma in South East Asia Recommendations 2021 · Florida State University, University of Nevada, Las Vegas, Manipal Academy of Higher Education, State University of New York Downstate Health Sciences University

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---